Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals Stock Forecast

Stock Price Forecast

The 24 analysts with 12-month price forecasts for REGN stock have an average target of 1,111, with a low estimate of 895 and a high estimate of 1,300. The average target predicts an increase of 45.75% from the current stock price of 762.00.

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$895	$1,111	$1,135	$1,300
Change	+17.45%	+45.75%	+48.95%	+70.60%

Analyst Ratings

The average analyst rating for REGN stock from 24 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jun '24	Jul '24	Aug '24	Sep '24	Oct '24	Nov '24
Strong Buy	7	7	8	8	8	8
Buy	12	12	11	11	11	12
Hold	5	4	4	5	4	4
Sell	1	1	1	1	1	0
Strong Sell	0	0	0	0	0	0
Total	25	24	24	25	24	24

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Alexandria Hammond Wolfe Research	Wolfe Research	Buy Initiates $1,150	Buy	Initiates	$1,150	+50.92%	Nov 15, 2024
Geoff Meacham Citigroup	Citigroup	Hold Initiates $895	Hold	Initiates	$895	+17.45%	Nov 14, 2024
Hartaj Singh Oppenheimer	Oppenheimer	Buy Maintains $1,150 → $1,000	Buy	Maintains	$1,150 → $1,000	+31.23%	Nov 6, 2024
Matthew Harrison Morgan Stanley	Morgan Stanley	Buy Maintains $1,235 → $1,184	Buy	Maintains	$1,235 → $1,184	+55.38%	Nov 1, 2024
Brian Abrahams RBC Capital	RBC Capital	Buy Maintains $1,260 → $1,215	Buy	Maintains	$1,260 → $1,215	+59.45%	Nov 1, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

14.45B

Increased by 10.13%

from 13.12B

Revenue Next Year

15.02B

Increased by 4.00%

from 14.45B

EPS This Year

45.84

Increased by 31.83%

from 34.77

EPS Next Year

46.12

Increased by 0.61%

from 45.84

Fiscal Year	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	6.56B	8.50B	16.07B	12.17B	13.12B	14.45B	15.02B	16.13B
Revenue Growth	27.44%	29.58%	89.14%	-24.26%	7.76%	10.13%	4.00%	7.36%
EPS	18.46	30.52	71.97	38.22	34.77	45.84	46.12	51.34
EPS Growth	-13.29%	65.33%	135.81%	-46.89%	-9.03%	31.83%	0.61%	11.32%
Forward PE	-	-	-	-	-	16.62	16.52	14.84
No. Analysts	-	-	-	-	-	30	30	25

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2024	2025	2026	2027	2028
High	15.3B	17.0B	19.0B
Avg	14.4B	15.0B	16.1B
Low	13.6B	12.1B	14.2B

Revenue Growth

Revenue Growth	2024	2025	2026	2027	2028
High	16.4%	17.6%	26.3%
Avg	10.1%	4.0%	7.4%
Low	3.3%	-16.1%	-5.3%

EPS Forecast

EPS	2024	2025	2026	2027	2028
High	49.55	54.55	67.06
Avg	45.84	46.12	51.34
Low	41.91	38.76	41.03

EPS Growth

EPS Growth	2024	2025	2026	2027	2028
High	42.5%	19.0%	45.4%
Avg	31.8%	0.6%	11.3%
Low	20.5%	-15.4%	-11.0%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.